More on BHVN

- Summary
- Chart
- Profile
- Historical

Data

- Earnings
- Ratings (6.8 Score)
- Holders
- Event Driven Deals

Upcoming Events

- Earnings (8/3/26)
- M&A (3/31/23 *Est)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Biohaven Pharma (NY:BHVN)
Delayed: 15.44 +1.27 (8.96%)
Prev. Close $14.17  
Open$13.74 
52 Wk High$ 
52 Wk Low$ 
Day High$15.51 
Day Low$13.62 
P/E N/A  
EPS$ 
Volume3,506,195 

Friends, Peers and Foes (?): QURE, REGN, ALKS, ALNY, BEAM (more...)

Jul 17, 2026 06:00 PM Form 3 Biohaven Ltd. For: Jul 09 Filed by: Volles Warren Karl
Jul 9, 2026 05:11 PM Form 8-K Biohaven Ltd. For: Jul 09
Jul 9, 2026 05:01 PM Biohaven names new discovery head as CSO shifts to part-time role
Jul 9, 2026 05:00 PM Biohaven Announces Scientific Leadership Transitions
Jul 8, 2026 05:44 PM Form SCHEDULE 13G/A Biohaven Ltd. Filed by: Janus Henderson Group Ltd.
Jun 30, 2026 07:31 AM Biohaven completes enrollment in focal epilepsy drug trial
Jun 30, 2026 07:30 AM Biohaven Completes Enrollment in RISE 3 Pivotal Focal Epilepsy Study with Opakalim, a Selective Kv7.2/7.3 Activator
Jun 29, 2026 03:27 PM Biohaven Pharma (BHVN) call put ratio 7.5 calls to 1 put as share price down 4.7%
Jun 29, 2026 11:51 AM BofA cuts ratings on four biopharma stocks over valuation and catalyst concerns
Jun 29, 2026 07:31 AM Biohaven starts Phase 3 trial of BHV-1300 for Graves' disease
View All Articles

Entities mentioned with BHVN

View All Entities